For fit patients with LR‐MDS, including SF3B1‐mutated MDS, there are ongoing trials regarding the potential benefit of early transplantation,70, 71 but for most patients, options remain supportive and non‐curative. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.